188968-51-6 Usage
Uses
Different sources of media describe the Uses of 188968-51-6 differently. You can refer to the following data:
1. Angiogenesis
inhibitor.
2. Cilengitide trifluoroacetic acid salt has been used as an inhibitor of integrin αvβ5.
Biochem/physiol Actions
It exhibits antitumor activity in glioblastoma multiforme tumors. Integrins are heterodimers of α and β chain. They are transmembrane receptors which are responsible for cell-to-cell and cell-extracellular matrix interactions. They control tumor angiogenesis, invasion and migration.
Check Digit Verification of cas no
The CAS Registry Mumber 188968-51-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,9,6 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 188968-51:
(8*1)+(7*8)+(6*8)+(5*9)+(4*6)+(3*8)+(2*5)+(1*1)=216
216 % 10 = 6
So 188968-51-6 is a valid CAS Registry Number.
InChI:InChI=1/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
188968-51-6Relevant articles and documents
Pharmaceutical composition comprising oligopeptides
-
Page/Page column 107, (2016/09/26)
The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingre
COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE
-
Paragraph 0589; 0590, (2015/11/09)
The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.
Cyclic RGD peptides of amino acids based on thiazoles or oxazoles as selective antagonists of the alpha-v beta-3 integrin
-
, (2012/06/05)
The present invention relates to compounds of general formula (I) with selective antagonist activity of the αvβ3 integrin, its production process, and pharmaceutical compositions and conjugates containing them. The invention also covers their medical and diagnostic uses and as carriers of other therapeutic agents.
